Hotline is provided by the ACR Communications and Marketing Committee as a service to members. Hotlines reflect the views of the author(s) and do not represent position statements of the College. Read our Hotline Guidelines.

Do you have a topic suggestion? ACR members are encouraged to for consideration!

• Tofacitinib for the Treatment of Rheumatoid Arthritis (12/12) 
• Update on Herpes Zoster (Shingles) Vaccine for Autoimmune Disease Patients (9/12)
• Pegloticase and Concomitant Urate-lowering Therapies (1/12)
• Fatal Infusion Reactions in Rheumatoid Arthritis Patients Treated with Rituximab (6/11)
• Tocilizumab Approved for the Treatment of Systemic Juvenile Idiopathic Arthritis (5/11)
• Rituximab in Granulomatosis with Polyangiitis (Wegener's) and Microscopic Polyangiitis (5/11)
• Belimumab for Systemic Lupus Erythematosus (3/11)
• Dietary Reference Intakes for Calcium and Vitamin D (12/10)
• Pegloticase for the Treatment of Gout (11/10)
• Denosumab (10/10)
• Atypical Femoral Fractures with Long-Term Bisphosphonate Use (3/10)
• Tocilizumab for the Treatment of Rheumatoid Arthritis (2/10)
• H1N1 Virus: Implications for Rheumatology (9/09)
• Herpes Zoster (Shingles) Vaccine Guidelines for Immunosuppressed Patients (8/08)
• New NOF Guidelines and the WHO Fracture Assessment Tool or FRAX (3/08)
• Zoledronic Acid (10/07)
• Rituximab and Progressive Multifocal Leukoencephalopathy (01/07)
• Bisphosphonate-Associated Osteonecrosis of the Jaw (06/06)
• Update on Safety Issues Concerning TNF Inhibitors (05/06)
• Abatacept and Rituximab (05/06)
• The Safety of COX-2 Inhibitors (03/05)
• Cardiovascular Complications Related to COX-2 Inhibitors (09/04)
• Health Professionals Follow-up Study on Gout: What Do We Now Tell Patients About Diet and Alcohol? (05/04)
• FluMist® Nasal Spray Influenza Vaccine: Implications for Rheumatology (10/03)
• The Use of Anti-cyclic Citrullinated Peptide (anti-CCP) Antibodies in RA (10/03)
• Update on the Safety of New Drugs for Rheumatoid Arthritis
  Part II: CHF, Infection and Other Safety Issues (08/03)
• Update on the Safety of New Drugs for Rheumatoid Arthritis
  Part III: Safety and Efficacy Update on Leflunomide (Arava®) (05/03)
• Update on the Safety of New Drugs for Rheumatoid
  Arthritis (03/03)
• Teriparatide (Forteo™) for the Treatment of Osteoporosis (01/03)
• Smallpox: Relevance to Rheumatology (12/02)
• New Therapies for Pulmonary Hypertension in Systemic Sclerosis (08/02)
• Update: Safety Issues Related to NSAIDs and COX-2 Inhibitors (4/02)
• Anakinra (Kineret® ™) FDA Approved for use in Rheumatoid Arthritis (11/01)
• FDA Advisory Committee Reviews Safety of TNF Inhibitors (09/01)
• Selective COX-2 Inhibitors as Risk Factors for Cardiovascular Events (08/01)
• Reports of Leflunomide Hepatotoxicity in Patients with Rheumatoid Arthritis (08/01)
• Methotrexate for Giant Cell Arteritis (03/01)
• Etanercept Patient Enrollment (12/00)
• Etanercept Update on Recent "Dear Doctor" Safety Letter (11/00)
• Rituximab in the Treatment of Rheumatoid Arthritis (11/00)
• Quality of Health Care for Rheumatoid Arthritis Patients: Another Vote Cast in Favor of Rheumatologists (10/00)
• New Data on Glucosamine and Chondroitin Sulfate (07/00)
• A Surgical Cure for Fibromyalgia and Chronic Fatigue? Reaction to an ABC News 20/20 Report (04/00)
• Infliximab (Remicade) Approved for Use in Rheumatoid Arthritis (02/00)

Read Hotlines from 1994-1999